Navigation Links
DaVita Abstracts Highlight Latest Research Developments at Annual Dialysis Conference
Date:3/10/2009

Abstracts Reveal Ground-breaking Information on Kidney Education and Modality Treatments

EL SEGUNDO, Calif., March 10 /PRNewswire-FirstCall/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research(R) (DCR), today unveils innovative research featured in five abstracts at the Twenty-ninth Annual Dialysis Conference (ADC) in Houston, TX. The spectrum of research includes developments in pediatric dialysis, home hemodialysis and CKD education. In particular, DaVita's Abstract on CKD education shows patients enrolled in the EMPOWER(TM) program are more likely to choose a fistula, the optimum form of vascular access, and take an active role in their care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

    The five abstracts unveiled today include:

          -- EMPOWERing Patients to Take Control of Kidney Disease
             Susan Wright, BSN, RN, Amy Bogan BSN, RN and Ajay Chokshi

          -- Case Study: Buttonhole Cannulation Technique with Keloid-Scarred
             Skin
             Sylvia Donato-Moore, BSN, RN, CNN

          -- Experience with Intradialytic Parenteral Nutrition at a Pediatric
             Hemodialysis Unit
             Kathleen Traficanti, BS, RD

          -- NxStage(R) Pureflow SL Culture and LAL Collection Using the NxStage
             Sample Bag
             Debbie Allen, RN, CNN

          -- Profiles of Successful Daily Home Hemodialysis Patient-Care
             Partner Dyads: From Mutual Benefits to Martydom
             Meg Wise, PhD, Dorian Shatell, MS, Kristi Klicko, CHES and Mary
             Showers, RN, CNN

DaVita Chief Medical Officer, Allen R. Nissenson, MD states, "DaVita is proud to be a part of ADC, which is an outstanding conference that solely focuses on dialysis. As a leader in clinical outcomes, and a provider who serves more than 1-in-4 dialysis patients in the nation, we will continue our research and the Relentless Pursuit of Quality(TM). Amongst DaVita's many research findings, we will share our early data from our EMPOWER Program pilot in 2008, demonstrating the importance of early CKD education."

The abstract focusing on the DaVita(R) EMPOWER(TM) program is especially significant as it is the first time data on this program has been released. The EMPOWER program is a series of educational classes where earlier stage CKD patients, starting in Stage 3, can learn more about kidney disease. DaVita nurses, renal dietitians and social workers use a multidisciplinary approach to educate patients. The EMPOWER program is provided at no charge to patients, and early results indicate educating patients before they begin dialysis will have an impact on their health and quality of life. Research shows patients who went through DaVita's EMPOWER program were more likely to have a fistula in place on their first outpatient dialysis treatment. According to studies, fistula patients have the fewest complications, such as infection or clotting, in comparison to any other access choices.

The abstract also indicates 35 percent of all EMPOWER educated patients chose a home modality, reflecting a stronger sense of patient independence and desire to be actively involved in their own care.

In addition to the abstracts, DaVita is pleased to have several invited speakers presenting, Dr. Kamyar Kalantar-Zahed, MD, one of DCR's intellectual research partners, has two presentations: Body Mass Index and Mortality, and Defining Protein Energy Wasting in Dialysis. Additionally, Dr. Nissenson and Dr. Robert Provnenzano, MD are featured speakers at ADC, and will discuss the topics of Elderly Peritoneal Dialysis Patients and Regulatory Issues and Economic Results.

DaVita, DaVita Clinical Research and EMPOWER and the Relentless Pursuit of Quality are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,400 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 110,000 patients. As part of DaVita's commitment to building a healthy, caring community, DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. For more information about DaVita, its kidney education materials and its community programs, please visit www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
2. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
3. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
6. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots
9. American Academy Of Orthopaedic Surgeons 2009 Annual Meeting Highlights and Hot Topics
10. New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
11. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Treated at Proton Therapy Centers & Forecast" report to their offering. ... The South Korean Proton ... market size in 2016. The Untapped Proton Therapy Market for ... in 2016. Proton Therapy plays an important role in ...
(Date:3/29/2017)... , March 29, 2017  Experts in the ... monitoring devices like  Soberlink Systems  as a model ... paper, published in early 2017, concluded that remote ... in managing patient recovery." The findings ... of Addiction Medicine, detail a range of variables ...
(Date:3/29/2017)... Calif. , March 29, 2017 ... for patients as the highest standard in quality ... Krypton Vision introduces its objective Wavefront-driven refraction technologies ... subjective approach. This enables an unprecedented level of ... - exceptional vision relegated to Topgun Navy fighter ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... , ... An inventor and manicurist from Greet, S.C., wants to offer people a new way ... maintain clean and healthy feet, so I know the importance of proper foot care," he ... designed the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate ...
(Date:3/30/2017)... ... March 30, 2017 , ... This ... to President Trump expressing their support for an independent Vaccine Safety Commission. Five ... and one medical journalist, will hold a press conference at 9:00 AM ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... In the ... to 300,000 people each year develop other types of metastatic brain tumors(3). Though most ... the brain(3). As efforts focus on finding more effective treatment options, the San ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... St. Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... Often called the "Spice of Life" or "Wonder Spice", it has been used for ... extensive use in the East," says Heshelow, author of " Turmeric: How to Use ...
Breaking Medicine News(10 mins):